-
ALSO READ
Alert mothers key to checking eye cancer in kids (Eye cancer awareness week begins May 12)
Promising cancer drug data helps AstraZeneca in Pfizer fight
Antiviral therapy may lower risk of liver cancer
Living cell signal discovery boon for cancer treatment
Brain cancer: Biomarker to predict chemotherapy's effectiveness
-
Doctors may very soon be able to detect lung cancer early in its stage with help of a blood biomarker.
A new study has shown that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer.
Researchers at Cleveland Clinic studied the blood serum of 284 subjects, 48 percent of whom were female with a mean age of 68 years. The subjects were diagnosed with adenocarcinoma or squamous lung cancer: 44 percent of those at stage I, 17 percent at stage II, and 39 percent at stage III. A control group of 194 patients-who matched the cancer patients in age, gender, smoking history, COPD, diabetes, and blood lipids were at risk for lung cancer but did not have the disease. There were 534 metabolites identified, with the concentration of 149 metabolites differing significantly between the cancer and control groups.
Peter J. Mazzone, MD, FCCP, Director of the Lung Cancer Program for the Respiratory Institute at Cleveland Clinic said that the study results showed that patients with lung cancer had altered metabolic processes. This information could lead to the development of a diagnostic biomarker for early detection of lung cancer.
The study abstract has been released in an online supplement of the journal CHEST.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU